









市場行情
/
股票
/
nasdaq-plx
/

Protalix Biotherapeutics Inc

PLX

1.780USD

+0.050+2.89%

交易中（美東）報價延遲15分鐘

143.01M總市值

23.75本益比TTM



Protalix Biotherapeutics Inc

1.780

+0.050+2.89%

概覽公司財務分析

概覽

公司

財務

分析

關於 Protalix Biotherapeutics Inc 公司

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.

Protalix Biotherapeutics Inc簡介



公司代碼PLX

公司名稱Protalix Biotherapeutics Inc

上市日期Sep 06, 2010

CEOBashan (Dror)

員工數量207

證券類型Ordinary Share

年結日Sep 06

公司地址2 University Plaza

城市HACKENSACK

上市交易所NASDAQ OMX – NASDAQ Basic Amex

國家United States of America

郵編07601

電話12016969345

網址https://protalix.com/

公司代碼PLX

上市日期Sep 06, 2010

CEOBashan (Dror)

Protalix Biotherapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Dror Bashan

President, Chief Executive Officer, Director

2.28M

Dr. Aharon Schwartz, Ph.D.

Independent Director

303.00K

+74.14%

Mr. Yaron Naos

Senior Vice President - Operations

207.30K

Ms. Gwen A. Melincoff

Independent Director

40.00

Dr. Pol F. Boudes, M.D.

Independent Director

40.00

Mr. Mike Moyer

Investor Relations

Mr. Amos Bar Shalev

Independent Director

Dr. Shmuel (Muli) Ben-Zvi, Ph.D.

Independent Director

Dr. Eliot Richard Forster, Ph.D.

Independent Chairman of the Board

Mr. Gilad Mamlok

Chief Financial Officer, Senior Vice President

名稱

名稱/職務

職務

持股

持股變動

Mr. Dror Bashan

President, Chief Executive Officer, Director

2.28M

Dr. Aharon Schwartz, Ph.D.

Independent Director

303.00K

+74.14%

Mr. Yaron Naos

Senior Vice President - Operations

207.30K

Ms. Gwen A. Melincoff

Independent Director

40.00

Dr. Pol F. Boudes, M.D.

Independent Director

40.00

Mr. Mike Moyer

Investor Relations

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

HIR Investments Ltd

5.86%

BlackRock Institutional Trust Company, N.A.

3.97%

Opaleye Management Inc.

3.21%

Bashan (Dror)

2.84%

Renaissance Technologies LLC

1.64%

其他

82.49%

持股股東

佔比

HIR Investments Ltd

5.86%

BlackRock Institutional Trust Company, N.A.

3.97%

Opaleye Management Inc.

3.21%

Bashan (Dror)

2.84%

Renaissance Technologies LLC

1.64%

其他

82.49%

股東類型

持股股東

佔比

Investment Advisor

8.57%

Corporation

5.86%

Hedge Fund

4.97%

Individual Investor

4.29%

Investment Advisor/Hedge Fund

3.55%

Research Firm

0.18%

Venture Capital

0.11%

Bank and Trust

0.09%

Pension Fund

0.06%

其他

72.32%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

176

12.24M

15.35%

+846.09K

2025Q2

183

18.79M

23.60%

+3.26M

2025Q1

182

19.45M

25.30%

+4.26M

2024Q4

169

15.65M

21.26%

-1.03M

2024Q3

162

14.11M

19.17%

-5.41M

2024Q2

163

16.36M

22.25%

-4.44M

2024Q1

143

16.45M

23.43%

-4.40M

2023Q4

145

17.20M

24.67%

-3.21M

2023Q3

142

16.45M

24.08%

-6.46M

2023Q2

132

16.38M

24.76%

-4.13M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

HIR Investments Ltd

4.71M

5.91%

Apr 30, 2025

BlackRock Institutional Trust Company, N.A.

3.00M

3.77%

+2.84M

+1741.73%

Jun 30, 2025

Bashan (Dror)

2.28M

2.86%

Apr 30, 2025

Renaissance Technologies LLC

1.62M

2.03%

+426.05K

+35.83%

Jun 30, 2025

Geode Capital Management, L.L.C.

826.33K

1.04%

+826.33K

Jun 30, 2025

Rubin (Eyal)

660.91K

0.83%

+90.91K

+15.95%

Apr 30, 2025

Northern Trust Global Investments Limited

689.88K

0.87%

+6.58K

+0.96%

Jun 30, 2025

Stratos Wealth Partners, Ltd.

350.00K

0.44%

+3.60K

+1.04%

Jun 30, 2025

State Street Investment Management (US)

444.24K

0.56%

+148.14K

+50.03%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

0.03%

Franklin US Small Cap Multifactor Index ETF

0.01%

iShares Russell 2000 Growth ETF

0.01%

Proshares Ultra Russell 2000

0.01%

Global X Russell 2000 ETF

0.01%

Invesco Russell 2000 Dynamic Multifactor ETF

0.01%

DFA Dimensional US Sustainability Core 1 ETF

ProShares UltraPro Russell2000

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Avantis International Small Cap Equity ETF

iShares Micro-Cap ETF

佔比0.03%

Franklin US Small Cap Multifactor Index ETF

佔比0.01%

iShares Russell 2000 Growth ETF

佔比0.01%

Proshares Ultra Russell 2000

佔比0.01%

Global X Russell 2000 ETF

佔比0.01%

Invesco Russell 2000 Dynamic Multifactor ETF

佔比0.01%

DFA Dimensional US Sustainability Core 1 ETF

佔比0%

ProShares UltraPro Russell2000

佔比0%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

佔比0%

Avantis International Small Cap Equity ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Protalix Biotherapeutics Inc的前五大股東是誰？



Protalix Biotherapeutics Inc的前五大股東如下：
HIR Investments Ltd
持有股份：4.71M
佔總股份比例：5.91%。
BlackRock Institutional Trust Company, N.A.
持有股份：3.00M
佔總股份比例：3.77%。
Bashan (Dror)
持有股份：2.28M
佔總股份比例：2.86%。
Renaissance Technologies LLC
持有股份：1.62M
佔總股份比例：2.03%。
Geode Capital Management, L.L.C.
持有股份：826.33K
佔總股份比例：1.04%。